Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00019136 · ClinicalTrials.gov registry record · Phase 1
Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer
A Phase 1 study, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
NCT00019136: Completed Phase 1 study, sponsored by National Cancer Institute (NCI).
NCT00019136 is a Phase 1 study that has completed, run by National Cancer Institute (NCI). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00019136, a Phase 1 study, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
Study Summary
RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill ovarian cancer cells. Interleukin-2 combined with white blood cells that are gene-modified to recognize and kill ovarian cancer cells may be an effective treatment for recurrent or residual ovarian cancer. PURPOSE: Phase I trial to study the effectiveness of interleukin-2 plus gene-modified white blood cells in treating patients who have advanced ovarian epithelial cancer.
Interventions
- BIOLOGICAL aldesleukin
- BIOLOGICAL therapeutic allogeneic lymphocytes
- BIOLOGICAL MOv-gamma chimeric receptor gene
Trial Details
| Field | Value |
|---|---|
| Start Date | 1997-02 |
| Phase | Phase 1 |
What the finished NCT00019136 record still lists
NCT00019136 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which aldesleukin is the first listed.
NCT00019136 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00019136 about?
NCT00019136 is a clinical study titled "Gene Therapy and Biological Therapy in Treating Patients With Ovarian Epithelial Cancer". RATIONALE: Interleukin-2 may stimulate a person's white blood cells to kill ovarian cancer cells. Interleukin-2 combined with white blood cells that are gene-modified to recognize and kill ovarian cancer cells may be an effective treatment for recurrent or residual ovarian cancer. PURPOSE: Phase I ...
What is the current status of trial NCT00019136?
This trial is currently completed. It is a Phase 1 study. The study started on 1997-02.
What interventions are being tested in trial NCT00019136?
The interventions under investigation include: aldesleukin (BIOLOGICAL), therapeutic allogeneic lymphocytes (BIOLOGICAL), MOv-gamma chimeric receptor gene (BIOLOGICAL).
Who is sponsoring clinical trial NCT00019136?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia